Welcome to our dedicated page for Phibro Animal SEC filings (Ticker: PAHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Phibro Animal Health Corporation (Nasdaq: PAHC) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into Phibro’s animal health, mineral nutrition, and performance products businesses, as well as its governance, capital structure, and risk disclosures.
Key documents for PAHC include annual reports on Form 10-K and quarterly reports on Form 10-Q, where Phibro presents audited and interim financial statements, segment information for Animal Health, Mineral Nutrition, and Performance Products, and management’s discussion of factors affecting net sales, gross profit, operating expenses, and tax rates. These reports also describe product categories such as medicated feed additives, nutritional specialty products, vaccines, mineral nutrition products, and performance products.
Current reports on Form 8-K are particularly useful for tracking material events. For Phibro, recent 8-K filings have covered quarterly and annual financial results, updates to financial guidance, dividend declarations on Class A and Class B common stock, and a planned leadership transition in which Jack C. Bendheim is expected to move to an Executive Chairman role and Daniel (Dani) Bendheim is expected to become Chief Executive Officer and President as of a specified effective date. Other 8-K items document stockholder meeting results, including votes on director elections, advisory votes on executive compensation, and ratification of the independent registered public accounting firm.
Phibro’s definitive proxy statement (DEF 14A) provides extensive detail on corporate governance, Board structure, executive compensation philosophy and programs, related party transactions, and security ownership of certain beneficial owners and management. It also explains the voting rights of Class A and Class B common stock and the matters presented at the annual meeting.
On Stock Titan, AI-powered tools can help summarize lengthy filings such as 10-Ks, 10-Qs, 8-Ks, and proxy statements for PAHC, highlighting segment performance, notable risk or governance disclosures, and key decisions by the Board and stockholders. Users can also review filings related to dividends and other corporate actions, and, where available, monitor insider and beneficial ownership information reported in SEC forms. Real-time updates from EDGAR ensure that new Phibro filings appear promptly, while AI-generated overviews make it easier to understand the implications of complex regulatory documents.
Phibro Animal Health Corporation (PAHC) reports operations focused on animal health, including antibacterials, anticoccidials, nutritional specialties and vaccines, and discloses material risks, strategy and financial structure. The company highlights product families (e.g., Mecadox, Stafac, Bovatec, Terramycin) and vaccine platforms, expansion of vaccine production in Sligo, Ireland and a new facility in Guarulhos, Brazil, and ongoing microbial and bioproduct development. It identifies regulatory and market risks related to antimicrobial use classifications, potential restrictions under FDA guidance (including Guidance 273 and GFI 152), and reputational and demand impacts from consumer and regulatory actions. The company describes its 2024 Credit Facilities (term loans and a $310,000 revolving commitment) and existing indebtedness, interest rate hedges fixing portions of floating-rate debt, and availability under the revolver. Governance and capital structure details include Class A and Class B share counts and voting structures, dividend per share of $0.12 payable September 24, 2025, equity incentive plan metrics and RSU vesting conditions tied to 90-day average stock price thresholds. Audited financials by PwC are noted.
Phibro Animal Health Corporation (PAHC) filed a Form 144 reporting a proposed sale of 264,000 shares of Class A Common Stock through Goldman Sachs & Co. LLC with an approximate aggregate market value of $8,250,000. The filing lists 20,367,574 shares outstanding and an approximate sale date of 08/19/2025 on NASD. The shares were acquired on 04/14/2014 in a private placement from Phibro Animal Health Corporation, and the consideration is reported as an exchange of securities. The filer states there were no securities sold by the selling person in the past three months and includes the standard signature representation that the person does not possess undisclosed material adverse information.
Phibro Animal Health Corporation (PAHC) reporting person Larry Lee Miller, Chief Operating Officer, was granted 5,184 restricted stock units (RSUs) on 08/15/2025. After the grant, Mr. Miller beneficially owns 35,184 shares of Class A Common Stock. The RSUs are contingent rights to receive one share per RSU and vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to his continued employment through each vesting date. The Form 4 was signed by an attorney-in-fact on 08/19/2025. The filing discloses a routine equity award to an executive with time-based vesting; no option exercises, sales, or derivative transactions are reported.
Judith Weinstein, Senior Vice President, General Counsel and Corporate Secretary of Phibro Animal Health Corp (PAHC), was granted 3,447 restricted stock units (RSUs) on 08/15/2025. Each RSU represents a contingent right to receive one share of Class A common stock and the reported ownership following the grant is 3,447 shares (direct). The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to continued employment through each vesting date. The Form 4 was signed and dated 08/19/2025.
David Glenn, Chief Financial Officer of Phibro Animal Health Corporation (PAHC), received a grant of restricted stock units (RSUs). The Form 4 reports an acquisition dated 08/15/2025 of 4,845 RSUs at a $0 price, bringing his total beneficial ownership to 34,845 shares of Class A Common Stock. The RSUs each represent a contingent right to one share and vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to continued employment. The filing was signed by an attorney-in-fact on 08/19/2025. The disclosure reflects a routine executive equity award with time-based vesting.
Jonathan Bendheim, a director of Phibro Animal Health Corp (PAHC), reported acquiring 3,268 restricted stock units (RSUs) on 08/15/2025. These RSUs are contingent rights to receive one share of Class A common stock each and were reported as acquired at a $0 price. Following the reported transaction, Mr. Bendheim beneficially owns 3,268 shares (direct). The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to his continued employment through each vesting date. The Form 4 was signed by an attorney-in-fact on 08/19/2025.
Daniel M. Bendheim, Executive Vice President, Corporate Strategy and a director of Phibro Animal Health Corporation (PAHC), reported a grant of 3,964 restricted stock units (RSUs) on 08/15/2025. The RSUs represent contingent rights to receive one share of Class A Common Stock per unit and were awarded at $0 purchase price. The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to continued employment through each vesting date. The Form 4 was signed by an attorney-in-fact on 08/19/2025.
Jack Bendheim, who is listed as a director, 10% owner and President and CEO of Phibro Animal Health Corp (PAHC), reported a non‑derivative acquisition on 08/15/2025 of 16,840 restricted stock units (RSUs). Each RSU represents a contingent right to one share of Class A common stock and was reported at a $0 price.
The filing shows 76,320 shares beneficially owned by the reporting person after the transaction. The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to continued employment. The Form 4 was signed by an attorney‑in‑fact on behalf of Mr. Bendheim on 08/19/2025.
Insider grant of restricted stock units to a senior officer at Phibro Animal Health (PAHC). Lisa Ann Escudero, Senior Vice President, Human Resources, was awarded 2,152 restricted stock units (RSUs) on 08/15/2025. Each RSU represents the contingent right to receive one share of Class A Common Stock and was reported with a transaction code indicating a grant at $0. The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, provided the reporting person remains employed through each vesting date. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 08/19/2025.
Anthony Andolino, Vice President Finance and Treasurer of Phibro Animal Health Corp (PAHC), received an award of 1,793 restricted stock units (RSUs) on 08/15/2025. Each RSU represents a contingent right to one share of Class A common stock and was granted at a $0 price. The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to continued employment through each vesting date. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Andolino on 08/19/2025.